Want to see HK:8622 full AI Analyst Report?
Huakang Biomedical Holdings Company Limited (8622) AI Stock Analysis
Huakang Biomedical Holdings Company Limited
(HKEX:8622)
The score is primarily constrained by persistent losses and substantial cash burn, despite strong revenue growth, resilient gross margins, and conservative leverage. Positive technical momentum provides some support, but the negative P/E and absence of dividend income further limit the investment profile.
Huakang Biomedical Holdings Company Limited (8622) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 123.71M
- Dividend Yield
- ―
- Average Volume (3M)
- 212.28K
- Price to Earnings (P/E)
- -16.2
- Beta (1Y)
- 0.36
- Revenue Growth
- 30.60%
- EPS Growth
- -6.86%
- Country
- Hong Kong
- Employees
- 101
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Huakang Biomedical Holdings Company Limited Business Overview & Revenue Model
Company Description
Huakang Biomedical Holdings Company Limited operates as an investment holding firm, primarily dedicated to the research, development, manufacturing, marketing, and distribution of in-vitro diagnostic (IVD) reagents within the People's Republic of Chi...
Huakang Biomedical Holdings Company Limited Financial Statement Overview
Summary
Revenue growth, solid gross margins, low leverage, and a stable equity base are positives. However, persistent operating and net losses, negative operating cash flow, and recurring free-cash-flow deficits materially weaken financial quality.
Income Statement
37NegativeBalance Sheet
62PositiveCash Flow
24Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 32.51M | 28.28M | 25.36M | 24.63M | 25.33M | 26.13M |
| Gross Profit | 19.92M | 17.77M | 17.07M | 16.09M | 16.91M | 16.46M |
| EBITDA | -2.54M | -4.17M | -1.68M | -2.55M | 188.00K | -852.00K |
| Net Income | -5.07M | -5.01M | -4.16M | -5.78M | -3.08M | -4.22M |
Balance Sheet | ||||||
| Total Assets | 66.21M | 66.64M | 65.22M | 65.31M | 66.40M | 67.06M |
| Cash, Cash Equivalents and Short-Term Investments | 39.23M | 41.96M | 36.49M | 32.94M | 33.30M | 36.21M |
| Total Debt | 7.66M | 4.96M | 4.08M | 5.14M | 1.88M | 1.78M |
| Total Liabilities | 17.09M | 15.46M | 11.17M | 14.30M | 9.88M | 9.36M |
| Stockholders Equity | 49.07M | 51.15M | 54.05M | 51.02M | 56.52M | 57.70M |
Cash Flow | ||||||
| Free Cash Flow | -7.21M | -3.29M | -5.05M | -1.55M | 475.00K | -4.71M |
| Operating Cash Flow | -6.10M | -2.21M | -3.06M | -48.00K | 1.29M | -2.38M |
| Investing Cash Flow | -1.88M | 2.32M | -4.42M | -1.15M | -6.11M | -2.06M |
| Financing Cash Flow | 5.13M | 4.78M | 6.30M | 1.02M | 2.32M | -1.37M |
Huakang Biomedical Holdings Company Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:8622, the sentiment is Positive. The current price of 0.23 is above the 20-day moving average (MA) of 0.19, above the 50-day MA of 0.18, and below the 200-day MA of 0.26, indicating a neutral trend. The MACD of 0.01 indicates Negative momentum. The RSI at 65.32 is Neutral, neither overbought nor oversold. The STOCH value of 79.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:8622.
Huakang Biomedical Holdings Company Limited Peers Comparison
Overall Rating
HK:089758.6Neutral
HK:091157Neutral
HK:085854Neutral- HK:862247Neutral
HK:045544Neutral
HK:149842Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:0897 | 59Neutral | HKD 401.18M | 100.00 | 0.34% | ― | -8.30% | -44.44% |
| HK:0911 | 57Neutral | HKD 53.38M | 13.29 | 1.02% | ― | -18.16% | ― |
| HK:0858 | 54Neutral | HKD 147.90M | -0.13 | -154.56% | ― | -7.12% | -523.61% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:8622 | 47Neutral | HKD 118.56M | -16.19 | -10.11% | ― | 30.60% | -6.86% |
| HK:0455 | 44Neutral | HKD 191.35M | -2.73 | -14.55% | ― | 12.89% | -2.56% |
| HK:1498 | 42Neutral | HKD 123.04M | -4.04 | -21.66% | ― | -6.71% | 43.14% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:8622 | Huakang Biomedical Holdings Company Limited | 0.23 | -0.24 | -51.06% | |
| HK:0858 | Extrawell Pharmaceutical Holdings Limited | 0.05 | -0.04 | -44.57% | |
| HK:0455 | Tianda Pharmaceuticals Ltd. | 0.09 | -0.05 | -34.07% | |
| HK:0897 | Wai Yuen Tong Medicine Holdings Limited | 0.36 | -0.10 | -21.74% | |
| HK:0911 | Qianhai Health Holdings Ltd. | 0.32 | -0.03 | -7.35% | |
| HK:1498 | PuraPharm Corp. Ltd. | 0.23 | -0.19 | -45.24% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 29, 2026